Doryx Shortage Update: What Patients Need to Know in 2026

If you've been having trouble getting Doryx filled, you may be wondering: is there an official shortage? Is this going to get better or worse? Here is the most up-to-date information available in 2026 on Doryx and doxycycline availability, the history of supply challenges, and what you can do to ensure you get your medication.

Is There an Official Doryx Shortage in 2026?

The availability picture for Doryx in 2026 is nuanced. There is no active FDA-declared nationwide shortage of Doryx MPC (the current branded formulation manufactured by Mayne Pharma) as of 2026. However, patients regularly report difficulty finding it at pharmacies because it is a specialty brand with limited distribution — many pharmacies simply don't keep it in stock.

Additionally, the original Doryx formulation (older delayed-release tablets) was discontinued from the U.S. market, which adds to the confusion — some patients and pharmacies are still adjusting to the transition to Doryx MPC as the only available branded form.

Generic doxycycline hyclate — the active ingredient in Doryx — experienced significant national shortages in 2023 and 2024. That supply situation has largely improved by 2026, but spot shortages of specific generic formulations and strengths still occur in some regions.

A History of Doxycycline Shortages

Understanding why availability problems happen requires knowing the history. Doxycycline has been on the FDA's shortage list multiple times:

2013: The FDA reported a nationwide shortage of doxycycline hyclate due to manufacturing issues and increased demand. The CDC issued guidance for providers on managing with limited supply.

2023–2024: Demand for doxycycline surged unexpectedly — partly due to the rising adoption of DoxyPEP (using doxycycline after potential STI exposure to reduce the risk of chlamydia, syphilis, and gonorrhea). Public health agencies began recommending DoxyPEP in 2023, and manufacturers had not planned production schedules around this new demand. Multiple manufacturers also experienced production slowdowns, tightening supply further.

2026: Supply has improved for generic doxycycline hyclate capsules. Doryx MPC (brand) is available but not consistently stocked at most pharmacies due to its high cost and specialized market position.

Root Causes of the Doxycycline Supply Problem

Several structural factors make doxycycline — and therefore Doryx — vulnerable to supply problems:

Concentrated API sourcing: Research from the U.S. Pharmacopeia found that approximately 24% of doxycycline hyclate capsule production comes from Jordan — a region with ongoing geopolitical instability. Disruptions in this region ripple through global doxycycline supply.

Limited manufacturer base: Only a handful of companies manufacture doxycycline. When one has a problem, there aren't enough backup suppliers to quickly compensate.

Unpredictable demand spikes: New clinical guidelines — like the 2023 DoxyPEP recommendations — can rapidly increase demand for doxycycline in ways manufacturers can't quickly accommodate.

Uneven distribution: Even during adequate national supply, large chain pharmacies often receive priority allocation, leaving smaller and independent pharmacies with less stock.

What This Means for Doryx MPC Specifically

Doryx MPC has an additional layer of availability challenge beyond the generic doxycycline market. As a brand-only product (the authorized generic has had limited commercial launch), Doryx MPC competes for the same distribution infrastructure as generic doxycycline while also contending with its own high price point, which reduces how much pharmacies are willing to stock speculatively.

The good news is that the Mayne Pharma manufacturing of Doryx MPC appears stable. The primary challenge for patients in 2026 is not a manufacturing crisis but rather distribution gaps — getting the drug from where it exists to the specific pharmacy where you need it.

What Patients Can Do Right Now

Use medfinder: medfinder calls pharmacies near you to find which ones have Doryx MPC in stock and can fill your prescription. This is the most direct way to cut through the distribution gap.

Ask your pharmacy to order it: Even if Doryx MPC isn't on the shelf, most pharmacies can order it within 1–3 business days.

Ask your prescriber about alternatives: Generic doxycycline hyclate (with adjusted dosing), minocycline, or sarecycline may be appropriate alternatives for your situation.

Use savings programs: If cost is the barrier rather than availability, Mayne Pharma's patient savings card and GoodRx coupons can dramatically lower your out-of-pocket costs for Doryx MPC.

How to Track Shortage Status

The FDA's Drug Shortage Database at accessdata.fda.gov is the official source for current and resolved drug shortages. The ASHP (American Society of Health-System Pharmacists) also maintains a shortage list. If there is an active FDA shortage for doxycycline formulations, it will be listed there with details on affected manufacturers and expected resolution timelines.

The Bottom Line

Doryx MPC's availability in 2026 is more of a distribution and market challenge than an acute manufacturing shortage. The drug exists; getting it to your pharmacy is the obstacle. Understanding why this happens — and using tools like medfinder to navigate it — gives patients the best chance of getting their prescription filled quickly. For more background, read our guide on why Doryx is so hard to find.